Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/29778
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBargieri, Daniel Y. [UNIFESP]
dc.contributor.authorRosa, Daniela S. [UNIFESP]
dc.contributor.authorSimoes Lasaro, Melissa Ang
dc.contributor.authorFerreira, Luis Carlos S.
dc.contributor.authorSoares, Irene S.
dc.contributor.authorRodrigues, Mauricio M. [UNIFESP]
dc.date.accessioned2016-01-24T13:48:45Z-
dc.date.available2016-01-24T13:48:45Z-
dc.date.issued2007-06-01
dc.identifierhttp://dx.doi.org/10.1590/S0074-02762007005000039
dc.identifier.citationMemorias Do Instituto Oswaldo Cruz. Rio de Janeiro, Rj: Fundaco Oswaldo Cruz, v. 102, n. 3, p. 313-317, 2007.
dc.identifier.issn0074-0276
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29778-
dc.description.abstractRecently, we generated two bacterial recombinant proteins expressing 89 amino acids of the C-terminal domain of the Plasmodium vivax merozoite surface protein-1 and the hexa-histidine tag (His6MSP1(19)). One of these recombinant proteins contained also the amino acid sequence of the universal pan allelic T-cell epitope (His(6)MSP1(19)-PADRE). in the present study, we evaluated the immunogenic properties of these antigens when administered via the intra-nasal route in the presence of distinct adjuvant formulations. We found that C57BL/6 mice immunized with either recombinant proteins in the presence of the adjuvants cholera toxin (CT) or the Escherichia coli heat labile toxin ( LT) developed high and long lasting titers of specific serum antibodies. the induced immune responses reached maximum levels after three immunizing doses with a prevailing IgG1 subclass response. in contrast, mice immunized by intranasal route with His(6)MSP1(19)-PADRE in the presence of the synthetic oligonucleotides adjuvant CpG ODN 1826 developed lower antibody titers but when combined to CT, CpG addition resulted in enhanced IgG responses characterized by lower IgG1 levels. Considering the limitations of antigens formulations that can be used in humans, mucosal adjuvants can be a reliable alternative for the development of new strategies of immunization using recombinant proteins of P. vivax.en
dc.format.extent313-317
dc.language.isoeng
dc.publisherFundaco Oswaldo Cruz
dc.relation.ispartofMemorias Do Instituto Oswaldo Cruz
dc.rightsAcesso aberto
dc.subjectPlasmodium vivaxen
dc.subjectmucosal immunizationen
dc.subjectrecombinant vaccinesen
dc.subjectadjuvantsen
dc.titleAdjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal routeen
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.description.affiliationUniversidade Federal de São Paulo, Dept Microbiol Imunol Parasitol, Escola Paulista Med, BR-04044010 São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Ctr Interdisciplinar Terapia Genica, Escola Paulista Med, BR-04044010 São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Dept Microbiol, Inst Ciencias Biomed, São Paulo, Brazil
dc.description.affiliationUniv São Paulo, Dept Anal Clin & Toxicol, Fac Ciencias Farmaceut, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Microbiol Imunol Parasitol, Escola Paulista Med, BR-04044010 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Ctr Interdisciplinar Terapia Genica, Escola Paulista Med, BR-04044010 São Paulo, Brazil
dc.identifier.fileS0074-02762007000300010.pdf
dc.identifier.scieloS0074-02762007005000039
dc.identifier.doi10.1590/S0074-02762007005000039
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000247965700010
Appears in Collections:Em verificação - Geral

Files in This Item:
File SizeFormat 
S0074-02762007000300010.pdf379.29 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.